For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

This guarantee provides peace of mind for potential customers and reflects the brand ... COPD, promotes deeper breathing, targets mucus buildup, and provides a natural alternative to inhalers ...

Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...

We assessed socioeconomic covariates (mean copayments, total copayments, and unique brand-to-generic prescription ... glycopyrrolate-formoterol. Dry powder inhalers may not be suitable for all ...

3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

A new year, new breakthroughs! Join us for our annual tradition of compiling and revealing the most interesting things ...

Asthma inhalers are hand-held devices that allow you to inhale a dose of medication to treat asthma symptoms. There are many types of asthma inhalers. They differ in whether they're used for quick ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.